



FOR IMMEDIATE RELEASE

October 6, 2015

Press Contacts:

Genalyte

Media Relations

media@genlayte.com

KCAS

Christine Frankovic

Sr. Director, Business Development

Office: 650.394.4370

christine.frankovic@kcasbio.com

KCAS Bioanalytical & Biomarker Services and Genalyte Announce the Availability of GLP-compliant Assays on the Maverick™ Detection System

KANSAS CITY, KS and SAN DIEGO, CA—KCAS Bioanalytical & Biomarker Services, a small and large molecule Good Laboratory Practices (GLP)-compliant bioanalytical and biomarker contract research organization (CRO), and Genalyte, Inc., a next-generation clinical and diagnostic life science detection company, announced today a collaborative agreement for KCAS to provide services using Genalyte's multiplexed Maverick™ Detection System.

The Maverick platform uses a proprietary silicon chip containing arrays of photonic microring sensors to simultaneously analyze multiple proteins or biomarkers from a single 5µl sample, using a one-step process that automates the washes, incubations, reagents and processing steps associated with other technologies.

"KCAS has been providing quality data in a timely fashion using traditional platforms for more than 36 years. We are excited to expand our line-up of GLP and non-GLP options with the Maverick Detection System and offer this innovative technology to the scientific community for support of preclinical and clinical trials." said Michael Lanman, Vice President of Operations at KCAS Bioanalytical & Biomarker Services. "The quality, sensitivity, low sample volume, and high throughput of the Maverick meets a growing need for our customers who have immunogenicity and biomarker needs. We welcome the opportunity to collaborate with Genalyte. We look forward to a productive, long-term partnership."

Alex Batchelor, Head of Sales and Marketing at Genalyte, said, "Many of our customers are required to send samples for testing in a GLP-compliant setting at contract research organizations. For this reason, we introduced the Authorized Service Provider concept and we are very pleased to have partnered with KCAS under this program. KCAS provides both GLP and non-GLP analytical services that can be accessed

by customers who want to use our autoimmune and immunogenicity products in a GLP-compliant setting.”

Genalyte’s Maverick Detection System and its human Multi-Tier Anti-Drug Antibody (MT-ADA) assay simultaneously screen, confirm, and characterize anti-drug antibodies with extremely high drug tolerance, and their autoimmune kits are currently commercially available to researchers. The autoimmune assays simultaneously screen for several of the most common autoantibodies found in connective tissue disorders, such as systemic lupus erythematosus (SLE). The simplified one-step workflow of the Maverick assays delivers accurate results in 15 minutes, and they can be run using very small volume samples from a variety of matrices, including serum and plasma.

For more information about Genalyte, the Maverick platform, hMT-ADA, autoimmune assay kits, and Genalyte’s Custom Chip Spotting Service, visit www.genalyte.com. Maverick assays are currently available for research use only.

About Genalyte

Founded in 2007, Genalyte is a company based on a simple premise: in the 21st century it is unacceptable that doctors, patients and researchers should have to wait days or even weeks for reliable bloodwork results. Genalyte is making this new standard a reality, merging silicon biosensor technology and established biological techniques to empower doctors and patients alike.

Genalyte’s technology is already being used by pharmaceutical companies and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and to test for infectious agents such as Ebola. By reducing the size of tests while rapidly increasing the speed of results, the Maverick Detection System generates more actionable information in less time than current techniques being used. Learn more at: www.genalyte.com

About KCAS Bioanalytical Services

KCAS Bioanalytical & Biomarker Services is a contract research organization (CRO) with 36+ years of bioanalytical expertise. We specialize in the development and validation of robust small molecule, large molecule and biomarker methods for discovery, preclinical and clinical studies. Our dedicated scientific and laboratory teams have an average tenure of 14 years, and have developed and validated more than 5,500 bioanalytical assays. Learn more at: www.kcasbio.com